HCPCS J9144: Daratumumab with Hyaluronidase, Subcutaneous Injection
HCPCS Level II code J9144 describes an injection of daratumumab with hyaluronidase provided as a subcutaneous oncology therapeutic dose (per 10 mg) for treatment of plasma cell disorders; service type: subcutaneous monoclonal antibody administration; typical site of service: outpatient oncology clinic or infusion/oncology treatment center (subcutaneous administration in a clinic setting).
Customize your policy alerts
Sign up for hcpcs J9144 policy alerts
Get alerted when payer policies referencing J9144 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial reimbursement for HCPCS J9144 centers near BUCA’s average commercial rate of $87, while individual payer distributions vary. Blue Cross Blue Shield shows a tight spread between the 25th and 75th percentiles ($52.00 to $57.00, range $5.00), and Cigna is effectively pinned at $55.60 across p25–p75 (range $0.00), indicating constrained variability. UnitedHealth Group and Aetna present wider interquartile spreads: UnitedHealth Group has p25–p75 from $55.60 to $63.60 (range $8.00), and Aetna’s interquartile span is $13.40 to $56.10 (range $42.70), the largest dispersion among listed payers.
Maxima and minima differ by payer but are not uniformly available; UnitedHealth Group and Aetna show higher maximums ($133.40 and $10015.20, respectively) while several payers have medians clustered near $55–$59. Blue Cross Blue Shield and Cigna display the most compressed IQRs, signaling consistent commercial positioning, whereas Aetna’s broad IQR indicates substantial variability in contracted commercial rates.